SARS-CoV-2 Spike antibody (RBD)
Quick Overview for SARS-CoV-2 Spike antibody (RBD) (ABIN6992289)
Target
See all SARS-CoV-2 Spike AntibodiesReactivity
Host
Clonality
Conjugate
Application
-
-
Binding Specificity
- RBD
-
Purification
- SARS-CoV-2 (COVID-19) Spike RBD antibody is affinity chromatography purified via peptide column.
-
Immunogen
- Anti-SARS-CoV-2 (COVID-19) Spike RBD antibody was raised against a peptide corresponding to 19 amino acids near the carboxy terminus of SARS-CoV-2 (COVID-19) Spike glycoprotein RBD. The immunogen is located within the last 50 amino acids of SARS-CoV-2 (COVID-19) Spike protein RBD.
-
Isotype
- IgG
-
-
-
-
Application Notes
-
WB: 2-5 μ,g/mL, IF: 20 μ,g/mL, IHC: 0.5 μ,g/mL.
Antibody validated: Western Blot in human samples, Immunohistochemistry and Immunofluorescence in human samples. SARS-CoV-2 (COVID-19) Spike RBD Antibody can be used for the detection of SARS-CoV-2 (COVID-19) Spike protein in ELISA and WB. It will detect 4 ng of free peptide at 1 μ,g/mL. All other applications and species not yet tested. -
Restrictions
- For Research Use only
-
-
-
Format
- Liquid
-
Concentration
- 1 mg/mL
-
Buffer
- SARS-CoV-2 (COVID-19) Spike RBD antibody is supplied in PBS containing 0.02 % sodium azide.
-
Preservative
- Sodium azide
-
Precaution of Use
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Storage
- -20 °C,4 °C
-
Storage Comment
- SARS-CoV-2 (COVID-19) Spike RBD antibody can be stored at 4°C for three months and -20°C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.
-
-
- SARS-CoV-2 Spike
-
Target Type
- Viral Protein
-
Background
- Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019-20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a Spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Coronavirus invades cells through Spike (S) glycoproteins, a class I fusion protein. It is the major viral surface protein that coronavirus uses to bind to the human cell surface receptor. It also mediates the fusion of host and viral cell membrane, allowing the virus to enter human cells and begin infection (3). The spike protein is the major target for neutralizing antibodies and vaccine development (4). The protein modeling suggests that there is strong interaction between Spike protein receptor-binding domain and its host receptor angiotensin-converting enzyme 2 (ACE2), which regulate both the cross-species and human-to-human transmissions of COVID-19 (5). The recent study has shown that the SARS-CoV-2 spike protein binds ACE2 with higher affinity than SARS-CoV spike protein (6).
-
Gene ID
- 43740568
Target
-